Alzheimer’s: The Disease That Steals Your Mind

Dementia: The Disease that Kills You While You’re Still Alive

Into the Shadows

In 2007, in Aichi Prefecture, Japan, an elderly man with Alzheimer’s disease left home during the kind of gap every caregiver knows and dreads. It was a few minutes when someone turns away, answers a door, washes a dish, tries to remain human.

He was 91 years old, and his wife, also elderly, had been helping to care for him through the long progression of his illness. His family had tried to prepare for the danger of wandering in the only way they knew how. According to Japanese reporting, identifying information had been sewn into his clothing so that, if he became lost, strangers could read it and help guide him home.

That morning, he managed to walk to a nearby station, board a train, and later enter the track area of another station along the line. He did not come home.

Then came the second shock. JR Central, one of Japan’s largest railway companies, sued his family. The company sought damages for the delays and disruption caused on its lines that day, and lower courts initially found family members liable for the loss.

The case climbed slowly through the Japanese legal system until it reached the country’s Supreme Court. At stake was a question much larger than one family or one morning at a rural station. When dementia destroys a person’s ability to judge risk, who becomes responsible for every door, every street, every platform edge, every impossible moment of supervision?

Who, exactly, is “we”?

A Door Opens in Aichi

The man at the center of the case had lived a long life in Aichi Prefecture, and by 2007 his Alzheimer’s disease had advanced to the point where he could no longer be safely left alone for long. His wife, then in her eighties, was his primary caregiver, and family members tried to share what they could of the watching and the worrying. Japanese reporting from the Asahi Shimbun later traced what happened on the day he disappeared, when a brief lapse in supervision opened a door that should have stayed closed.

He boarded a train from Obu Station, traveled a short distance, and ended up in the track area of Kyowa Station, where he was killed in an incident involving a passing train. JR Central calculated its losses from the resulting delays and went looking for someone to pay. The company demanded roughly 7.2 million yen in damages from the dead man’s relatives, arguing that the family had failed in its duty to supervise him.

A district court agreed with the railway, and so did the high court on first appeal, leaving the widow and her son legally on the hook for a moment of inattention in a years-long marathon of care. The judgment alarmed dementia advocates and aging-policy experts across Japan, because if the ruling stood, every family caring for a relative with cognitive decline would be one open door away from financial ruin. In March 2016, after years of appeals, the Supreme Court of Japan reversed the lower decisions and freed the family from liability, though the legal reasoning left as many questions open as it closed.

So this is where our story begins, and it is also where the larger argument of this episode begins. Dementia is a medical diagnosis, yes, but it is also a stress test that reaches far beyond the clinic and into the lives of everyone connected to the person who is changing. It tests hospitals and home aides, courts and insurance companies, drug regulators and nursing homes, neighbors who notice and neighbors who look away, and entire aging societies trying to decide how much risk a free person is allowed to carry. The Aichi case is one family’s tragedy, and it is also a question the rest of the world has not yet answered.

What Dementia Is Not

Before we go any further, it helps to be precise about what we are actually talking about, because the word “dementia” gets used loosely in ways that obscure what is happening inside a human brain. Dementia is not a single disease, and it is not a normal part of getting older, even though its risk does rise sharply with age. The World Health Organization describes it as a syndrome, which means a recognizable pattern of symptoms produced by a range of underlying diseases and injuries that damage the brain over time.

Those symptoms typically include progressive problems with memory, thinking, language, judgment, behavior, and the ordinary tasks of daily life like dressing, cooking, or handling money. The damage is biological, rooted in the death of brain cells and the breakdown of the networks that connect them, and at present most forms cannot be cured or reversed.

Alzheimer’s disease is the most common cause, accounting for somewhere between 60 and 70 percent of cases worldwide, which is why the two terms often get tangled together in everyday speech. Vascular dementia, caused by strokes and damaged blood vessels in the brain, is another major form, and so are Lewy body dementia and frontotemporal dementia, each with its own pattern of symptoms and progression. A person can also have more than one type at once, which complicates both diagnosis and treatment in ways that families rarely hear about until they are deep inside it.

Here’s the thing — normal aging can mean slower recall, the missing name that surfaces an hour later, the keys left on the wrong shelf. Dementia is something different in kind, because it steadily strips away the ability to live independently and to make sense of the ordinary world. The U.S. Centers for Disease Control puts it plainly on its public-facing pages: Alzheimer’s and other dementias are not a normal part of aging, even though older adults are far more likely to develop them.

One last note on language before we move on. Throughout this episode we will speak of people living with dementia, because that is the framing now used by major health bodies and advocacy groups, and because it keeps the person visible inside the diagnosis. A person with Alzheimer’s is still a person, often for many years after the first signs appear, and that fact will matter for almost every story that follows.

The Scale of the Long Goodbye

Zoom out from one household in Aichi, and the numbers become almost difficult to hold in the mind. The World Health Organization estimates that around 57 million people were living with dementia worldwide in 2021, with nearly 10 million new cases added each year. It is already one of the leading causes of disability and dependency among older adults on the planet, and the curve is bending upward rather than down.

A forecast published in The Lancet Public Health by researchers at the Institute for Health Metrics and Evaluation projects that the global figure could reach roughly 152.8 million people by the year 2050. The increase is driven largely by population aging, which means more people surviving long enough to enter the years when dementia risk climbs steeply. The biggest proportional rises are expected in parts of North Africa, the Middle East, and sub-Saharan Africa, regions where health systems have far fewer resources to absorb the load.

The financial weight is already staggering, and the WHO has put the global cost of dementia at around 1.3 trillion US dollars as of 2019, a figure that includes formal medical care and the vast informal labor of families. Roughly half of that cost is care provided by relatives and friends who are not paid for the hours they give, the sleep they lose, and the careers they shrink to keep someone safe at home. When economists try to price that work at even modest wage rates, the totals dwarf the budgets of entire national health systems.

Women carry the burden twice over in most countries, because they are more likely to be diagnosed with dementia in later life, partly because they live longer on average, and they are also more likely to be the daughter, wife, or sister who steps in to provide unpaid care for someone else. Studies cited by the WHO suggest that women provide the majority of informal dementia care hours globally, often while still holding paid jobs or raising children of their own.

Japan, where our opening story unfolded, sits at the leading edge of this demographic curve, with one of the oldest populations on earth and a dementia caseload that has already reshaped its courts, its trains, and its towns. Every other aging society is following along the same slope, just a few decades behind, which is one reason cases like the one in Aichi keep drawing international attention.

Auguste Deter Says “Lost”

To understand why a 91-year-old man in 2007 could walk out of his house and into a court case, we have to go back more than a century to a hospital in Frankfurt, Germany, and to a woman whose name medicine has never quite let go of. In November 1901, a 51-year-old patient named Auguste Deter was admitted to the Städtische Anstalt für Irre und Epileptische, the city’s institution for the mentally ill and epileptic, after her husband could no longer manage her at home. She was confused, fearful, and increasingly unable to recognize the people and objects around her, though she was still, by the standards of the day, a young woman.

Her doctor was Alois Alzheimer, a 37-year-old psychiatrist with a strong interest in the physical structure of the brain. He recorded her case in unusual detail, sitting with her, asking her questions, writing down her answers in clinical notebooks that would later be rediscovered and studied by historians of medicine. In one exchange preserved in those notes, Auguste was asked to write her own name, and after several failed attempts she said, in German, “Ich habe mich verloren,” which translates as “I have lost myself.”

Auguste Deter died in April 1906, after years of decline inside the institution, and Alzheimer asked for her brain to be sent to his laboratory in Munich for examination. Under the microscope, he saw two strange features in the tissue: dense clumps of protein scattered between the nerve cells, and twisted fibers tangled inside them. In a lecture delivered in November of that same year, he described what he had found in her case, linking her devastating symptoms in life to these specific physical changes in death.

The presentation did not cause an immediate sensation, and the audience reportedly moved on to other topics afterwards without much discussion. But a few years later, in 1910, the influential psychiatrist Emil Kraepelin included the condition in his major textbook and gave it the name by which the world now knows it, Alzheimer’s disease, after the doctor who had described Auguste’s brain. The patient herself, the woman who had said she was lost, faded from the public record for most of the twentieth century, until her original file was rediscovered in the 1990s and her face, her words, and her suffering returned to the story that bears her doctor’s name.

From “Senility” to Public Health

For most of the twentieth century, what Alois Alzheimer had described under his microscope sat in a strange medical limbo. Doctors knew the pathology existed, but in everyday practice, when an older person began to forget names and wander rooms, the diagnosis written down was usually “senility,” a word that carried the weight of inevitability rather than disease. Families absorbed the change in silence, often at home, often without help, because there was nothing useful to call it and almost nothing useful to do.

That began to shift in April 1976, when the neurologist Robert Katzman published an editorial in the Archives of Neurology arguing that Alzheimer’s disease and so-called senile dementia were the same illness, separated only by the age at which symptoms appeared. Katzman went further, calling the combined condition a major killer that had been hidden inside death certificates listing pneumonia, heart failure, or simple old age. The National Institute on Aging had been established two years earlier, in 1974, and Katzman’s argument gave the new institute a clear scientific target to pursue.

In 1980, a Chicago businessman named Jerome Stone, whose wife Evelyn had been diagnosed with Alzheimer’s, brought together a handful of small family support groups and founded what became the Alzheimer’s Association. The organization gave caregivers a place to call, researchers a constituency to fund, and the disease itself a name that ordinary Americans could finally use without shame. Still, for most of the 1980s, an Alzheimer’s diagnosis remained something families whispered about rather than announced.

The wall came down in public on November 5, 1994, when former United States President Ronald Reagan released a handwritten letter to the American people. He was 83 years old, five years out of the White House, and he wrote that doctors had told him he was one of the millions of Americans who would be afflicted with Alzheimer’s disease. “I now begin the journey that will lead me into the sunset of my life,” he wrote, and he said he hoped that by speaking openly he might promote greater awareness of the condition.

Reagan lived another decade inside that diagnosis, mostly out of public view, and he died in June 2004 at the age of 93. His letter did something that medical journals and advocacy brochures had not managed on their own, because it placed the disease inside one of the most recognizable lives of the century and asked the country to look directly at it. After 1994, donations to dementia research climbed, news coverage expanded, and the word Alzheimer’s started appearing in obituaries that had previously offered only “a long illness.”

The Brain Network Fails

To understand what Reagan was describing, it helps to picture the human brain as a vast web of around 86 billion nerve cells, each one talking to thousands of others through tiny junctions called synapses. Every memory you hold, every face you recognize, every sentence you understand is carried across that web by chemical and electrical signals firing in patterns built up over a lifetime. Alzheimer’s disease is, at its core, the slow corrosion of that web from inside the brain tissue itself.

Two proteins sit at the center of the story, and they are the same two structures that Alois Alzheimer drew from Auguste Deter’s brain in 1906. The first is amyloid beta, a sticky protein fragment that begins to clump together in the spaces between neurons, forming the dense plaques he saw scattered through her cortex. The second is tau, a protein that normally helps stabilize the internal scaffolding of a healthy nerve cell, but which in disease folds wrong and twists into tangled fibers inside the neuron itself.

Researchers still argue about which protein damages the brain first, and how exactly each one drives the disease, but the broad sequence is now reasonably well established. Amyloid begins to accumulate in the brain ten to twenty years before any symptoms appear, often while the person is still working, driving, raising a family, and feeling entirely well. Tau pathology follows, spreading from region to region in a pattern that researchers have mapped through hundreds of postmortem studies.

As these proteins accumulate, the brain’s immune cells, called microglia, switch into an inflammatory state and begin damaging the very tissue they were meant to protect. Synapses are pruned away faster than they can be rebuilt, and the connections that hold memories together start to thin out. The earliest losses concentrate in a small seahorse-shaped structure deep in the temporal lobe called the hippocampus, which acts as the brain’s gateway for forming new memories.

That is why the first symptom most families notice is not forgetting a childhood home but forgetting a conversation from an hour ago, or asking the same question three times in an afternoon. Old memories laid down decades earlier remain accessible for a long time, because they live in distributed networks across the cortex, while the machinery for laying down new ones is being dismantled first. As the disease spreads outward from the hippocampus into the rest of the cortex, language begins to fray, navigation fails, and judgment erodes in ways that are obvious to relatives long before they are obvious to the patient.

In the late stages of Alzheimer’s, the damage reaches regions of the brain that control swallowing, balance, and basic bodily regulation. People lose the ability to walk safely, then to eat without choking, and eventually to fight off the infections that follow when a body can no longer move or clear its own lungs. Most people with Alzheimer’s do not die from the plaques and tangles directly; they die from pneumonia, from falls, from the cascade of failures that follows when the brain can no longer manage the body it sits inside. That is why specialists, beginning with a 2009 paper widely covered by TIME magazine, pushed to have Alzheimer’s recognized as a terminal illness, on the same conceptual footing as advanced cancer or end-stage heart failure.

The proteins Alois Alzheimer drew in his notebook a century ago are still the proteins at the center of today’s drug trials, today’s PET scans, and today’s blood tests. Auguste Deter’s brain, in that sense, has never really left the laboratory.

Four Diseases Wearing One Mask

Alzheimer’s accounts for roughly 60 to 70 percent of dementia cases worldwide, according to the World Health Organization, but the remaining share is made up of conditions that look similar from the outside while behaving very differently inside the brain. Treating every case of cognitive decline as Alzheimer’s is one of the most common mistakes families and even some clinicians make, and it can lead to wrong medications, wrong expectations, and wrong plans for the years ahead.

Vascular dementia is the second-most common form, and it is caused by damage to the blood supply that keeps brain tissue alive. A major stroke can trigger it suddenly, leaving a person markedly changed within hours, but more often it builds up through a series of small, sometimes silent strokes and through the slow narrowing of tiny vessels deep inside the brain. Families often describe vascular dementia as a staircase rather than a slope, with long stable periods broken by sudden drops in ability after each new vascular event.

Lewy body dementia is named after the abnormal clumps of a protein called alpha-synuclein that collect inside neurons, the same protein that drives Parkinson’s disease in a different distribution. People with Lewy body dementia often experience vivid visual hallucinations early in the illness, along with dramatic fluctuations in alertness from one hour to the next. Movement symptoms similar to Parkinson’s, such as stiffness, tremor, and a shuffling walk, frequently appear alongside the cognitive changes, and sensitivity to certain antipsychotic drugs can make standard psychiatric treatment dangerous.

Frontotemporal dementia attacks a different territory of the brain, the frontal and temporal lobes, and it often strikes earlier in life than Alzheimer’s, sometimes in the fifties or even forties. Because the frontal lobes govern personality, judgment, and social behavior, the first signs are usually not memory loss at all. A previously cautious accountant might begin making reckless purchases, a gentle parent might become coarse or aggressive, a fluent speaker might start losing words and grammar while still remembering exactly where they parked the car.

Then there is mixed dementia, which research increasingly suggests may be the rule rather than the exception in older patients. Autopsy studies have found that many people diagnosed in life with Alzheimer’s also carried significant vascular damage, or Lewy bodies, or both, layered together inside the same brain. The neat textbook categories blur at the bedside, which is part of why diagnosis is so much harder than it sounds.

A handful of rarer conditions can also produce dementia, including Creutzfeldt-Jakob disease, a rapidly progressive prion disorder described by the Mayo Clinic, which can kill within months rather than years. These edge cases matter clinically, but they make up a tiny fraction of the global caseload that the WHO has been tracking.

The practical point is that the single word “dementia” hides at least four distinct biological stories, and the right care for one can be the wrong care for another. That difference will matter enormously when we come back, later in this episode, to the actor Robin Williams and the misdiagnosis that shadowed the final year of his life.

The First Signs Nobody Wants (with Pat Summitt)

In the spring of 2011, Pat Summitt was 58 years old and the most decorated coach in the history of American college basketball. Over 38 seasons at the University of Tennessee, she had won 1,098 games and eight national championships with the Lady Vols, and she was known across the sport for a level of mental precision that bordered on legend. She remembered plays from a decade earlier, she remembered the families of every player she had ever recruited, and she ran practices with the exactness of someone who never lost track of a detail.

That spring, she began losing track of details. Keys went missing, names slipped, plays she had drawn up a thousand times grew unfamiliar on the whiteboard, and the friction she felt inside her own thinking was unlike anything she had known in her life. She went to the Mayo Clinic for evaluation in May 2011, and the doctors there diagnosed her with early-onset Alzheimer’s disease at the age of 59.

On August 23, 2011, Summitt announced the diagnosis publicly through a statement released by the university. She coached one final season with significant support from her staff, retired in April 2012 with the title of head coach emeritus, and founded the Pat Summitt Foundation to fund Alzheimer’s research and patient services. She died on June 28, 2016, at the age of 64, from complications of the disease.

Her story is useful because the signs she first noticed are the signs that most families miss, dismiss, or rationalize for months and sometimes years before anyone consults a doctor. The World Health Organization and the U.S. Centers for Disease Control describe an overlapping cluster of early symptoms that tend to appear in the months and years before a formal diagnosis. People begin repeating the same questions in a single conversation, losing track of what day or season it is, struggling to find ordinary words like “watch” or “stairs,” and mishandling familiar tasks such as paying a recurring bill or following a recipe they have cooked for decades.

Personality changes are part of the picture too, and they can be subtler than the memory lapses. A sociable person may start withdrawing from gatherings they used to enjoy, a patient person may become unusually irritable, and a careful person may begin making decisions, especially financial ones, that close family members find baffling. Families tend to explain these changes through almost anything else first, reaching for grief, retirement, hearing loss, medication side effects, or simple stress before they reach for the possibility of dementia.

There is an intermediate stage that researchers call mild cognitive impairment, where measurable changes in memory or thinking are present but daily life still functions more or less normally. Not everyone with mild cognitive impairment goes on to develop dementia, and some people remain stable for years or even improve when an underlying cause is identified and treated. The threshold that most clinicians use for a dementia diagnosis is functional, meaning the changes have begun to interfere with independent living in a way that another person can clearly observe.

None of this means that an occasional lost word or misplaced phone is a sign of disease, and a single video on the internet is not the right tool for self-diagnosis. What Pat Summitt did, by going to a specialist as soon as she sensed the friction inside her own coaching, is what every major dementia organization recommends. Early evaluation can identify reversible causes, slow the progression in some cases, and give the person time to make decisions about their own life while they still hold the pen.

The Diagnosis Maze

Confirming a dementia diagnosis is harder than most families expect when they first walk into a neurologist’s office. There is no single blood test, no quick scan that returns a yes or no, and historically a definitive diagnosis of Alzheimer’s disease could only be made after death, when a pathologist examined the brain for the plaques and tangles that Alois Alzheimer first drew in 1906. Doctors working with living patients have to assemble the diagnosis from many smaller pieces.

The process usually begins with a detailed history taken from both the patient and a close family member, because people in the early stages of dementia often underestimate or hide the changes they are experiencing. Clinicians administer standardized cognitive tests that measure memory, attention, language, and visuospatial skills, and they look for patterns of impairment that fit one disease better than another. Bloodwork checks for treatable contributors such as thyroid disease, vitamin B12 deficiency, and certain infections, and brain imaging with MRI or CT scans rules out tumors, strokes, and a condition called normal pressure hydrocephalus that can mimic dementia closely.

That last category matters enormously, because a meaningful minority of patients who arrive looking like they have dementia actually have something else driving their symptoms. Depression in older adults can blunt memory and concentration so severely that it has its own clinical nickname, pseudodementia, and it often improves dramatically with treatment. Certain medications, especially those with anticholinergic effects, can produce confusion that lifts within weeks of stopping the drug. Sleep apnea, alcohol use, and chronic urinary tract infections can all push an older brain into a state that looks alarmingly like early Alzheimer’s until the underlying issue is addressed.

The biomarker era is changing this picture in real time. PET scans can now detect amyloid plaques in the living brain, cerebrospinal fluid drawn through a lumbar puncture can be analyzed for amyloid and tau, and blood-based tests for Alzheimer’s pathology have moved from research laboratories into early clinical use in several countries. These tools allow specialists to identify the disease earlier and more confidently than at any point in the history of the field, and they also raise difficult new questions about whether people want to know they carry the pathology years before symptoms begin.

Misdiagnosis remains a serious risk, particularly for Lewy body dementia and frontotemporal dementia, which can be mistaken for psychiatric illness, Parkinson’s disease, or simple personality change for years before the correct label is applied. Specialists at memory clinics see patients who have been on the wrong medications for half a decade because the original diagnosis was Alzheimer’s when the underlying disease was something else entirely.

A diagnosis, once made, sets a long sequence of decisions in motion that most families have never thought through. Driving privileges have to be evaluated, sometimes by the state and sometimes by a frank conversation at the kitchen table. Power of attorney, healthcare proxies, and advance directives need to be drafted while the person still has the legal capacity to sign them.

Financial accounts may need new safeguards, and conversations about long-term care, whether at home or in a facility, have to start years before they will actually be needed. We will return to that machinery of decisions later in this episode, when we look at what happened to one family in California after the diagnosis arrived.

Drugs That Help, Then Don’t Cure

So, with a diagnosis in hand, the next question every family asks is the obvious one. What can medicine actually do? The honest answer, in 2024, is more than it could do in 1990 and far less than the headlines often suggest.

The first drug specifically approved in the United States for Alzheimer’s disease was tacrine, cleared by the FDA in 1993 under the brand name Cognex. It worked by slowing the breakdown of acetylcholine, a neurotransmitter that nerve cells use to talk to one another and that runs short in Alzheimer’s brains. Tacrine produced modest cognitive benefits in some patients, but it also carried a significant risk of liver toxicity, and many people simply could not tolerate it for long. By the early 2010s it had been pulled from the U.S. market, eclipsed by newer drugs in the same family that were easier on the body.

Those newer drugs are the cholinesterase inhibitors most families today have actually heard of: donepezil, marketed as Aricept and approved in 1996, along with rivastigmine and galantamine, both approved later in the decade. They work along the same general principle as tacrine, boosting available acetylcholine to support the failing communication between neurons. For some patients, especially in mild to moderate Alzheimer’s, these medications produce a measurable improvement in memory and daily function that can last for months or sometimes a few years. For others, the benefit is small or absent, and the side effects, including nausea, diarrhea, and slowed heart rate, outweigh whatever gain there might be.

In October 2003, the FDA approved a fourth drug, memantine, sold as Namenda, for moderate-to-severe Alzheimer’s disease. Memantine works on a different chemical pathway, blunting overactivity of a brain chemical called glutamate that, in excess, appears to damage neurons. It is often added on top of a cholinesterase inhibitor in the later stages of the disease, and the combination has become a standard part of treatment in many memory clinics around the world.

Here is the part that families have to hear clearly, even when it is hard. None of these medications stops Alzheimer’s disease, and none of them brings back neurons that have already died. The plaques continue to accumulate, the tangles continue to spread, and the underlying biology grinds forward regardless of which pill is in the morning cup. What these drugs can do, in the patients who respond, is lift the symptoms slightly for a window of time, buying months of clearer conversation or steadier routine before the disease reasserts itself.

That is why supportive care has remained the backbone of dementia treatment for decades, not as an afterthought but as the main event. Consistent daily routines reduce confusion, familiar environments reduce agitation, and trained caregivers, whether family members or professionals, can prevent the falls, infections, and crises that often determine how long someone actually lives with the disease. Speech therapy, physical therapy, and structured activities have all been shown to help maintain function longer than medication alone. The World Health Organization, in its 2025 fact sheet on dementia, continues to frame care, not cure, as the central reality of treatment worldwide.

It was inside that frustrating gap, between drugs that softened symptoms and a disease that kept advancing, that the next chapter of Alzheimer’s research took shape.

The Amyloid Bet — and the Inheritance

In 1984, two researchers named George Glenner and Caine Wong, working at the University of California, San Diego, isolated and sequenced the protein that made up the dense plaques Alois Alzheimer had drawn almost eighty years earlier. They named it beta-amyloid, and their work opened a chemical door that the entire field would pour through over the following decades. Two years later, in 1986, several laboratories independently identified the tangled fibers inside neurons as twisted forms of a protein called tau, completing the molecular pair at the heart of the disease.

What came next was a hypothesis that has dominated Alzheimer’s research ever since, often called the amyloid cascade hypothesis. The idea, first articulated formally in the early 1990s, is that the abnormal buildup of beta-amyloid is the initiating event in Alzheimer’s disease, and that everything else, including the tau tangles, the inflammation, and the eventual death of neurons, flows downstream from that first protein going wrong. If amyloid is the upstream cause, then clearing amyloid from the brain should slow or stop the disease, and pharmaceutical companies have spent tens of billions of dollars over thirty years trying to do exactly that.

For most of those thirty years, the trials failed. Drug after drug reduced amyloid in the brain without producing meaningful improvement in patients, and a generation of researchers began openly questioning whether the field had bet too much on a single molecule. Skeptics argued that amyloid might be a byproduct of the disease rather than its driver, or that intervening at the plaque stage was simply too late to matter for someone already losing memory.

What kept the amyloid hypothesis alive through those failures was genetics, and specifically a small number of families in which Alzheimer’s disease passes down through the generations like clockwork. In the early 1990s, researchers identified mutations in a gene called APP, which codes for the amyloid precursor protein, in families where members reliably developed Alzheimer’s in their forties or fifties. Soon afterward, mutations in two related genes, presenilin 1 and presenilin 2, were linked to similar early-onset inherited forms of the disease, and all three genes turned out to affect how amyloid is produced and processed in the brain.

A separate genetic discovery, the APOE ε4 variant, identified in 1993, did not cause Alzheimer’s outright but significantly raised the risk of developing the more common late-onset form. People who inherit one copy of APOE ε4 are at elevated risk, and those who inherit two copies face risk levels several times higher than the general population. The genetic evidence pointed, again and again, back toward amyloid biology.

The most striking population in this story lives in the rural highlands of Antioquia, in northwestern Colombia, where an extended family of around six thousand related individuals carries a specific presenilin-1 mutation known as E280A, often called the Paisa mutation. Carriers reliably develop mild cognitive impairment in their mid-forties and full dementia by their early fifties, in a pattern that has been documented across generations by Colombian neurologist Francisco Lopera and his collaborators since the 1980s. The Paisa cohort has become one of the most important populations in global Alzheimer’s research, and prevention trials in this family are testing whether anti-amyloid treatments started before symptoms can delay the disease that their genes otherwise guarantee.

This is the science that sits behind the diagnosis Pat Summitt received in her fifties. Most early-onset Alzheimer’s is not inherited in the same dramatic pattern as the Paisa families, but the existence of those families, and the genes they carry, is part of why amyloid has remained at the center of the field even after so many failed drugs. The bet was scientific, it was expensive, and by the early 2020s it was about to face its sharpest public crisis yet.

The Image on the Slide

In July 2022, the journal Science published an investigation by reporter Charles Piller that shook the Alzheimer’s research community in a way nothing had in years. The reporting centered on Sylvain Lesné, a neuroscientist at the University of Minnesota, and on a 2006 paper he had co-authored in the journal Nature that had been cited thousands of times by other researchers in the field. The paper identified a specific subspecies of amyloid, called Aβ*56, as a possible toxic agent driving memory loss in animal models of Alzheimer’s disease.

The investigation was triggered by a Vanderbilt University neuroscientist named Matthew Schrag, who had been hired to examine images in scientific papers as part of a separate dispute over a different experimental Alzheimer’s drug. Schrag began noticing what looked like duplicated and altered bands in Western blot images, the laboratory pictures that researchers use to show the presence of specific proteins in their experiments. He compiled his findings and shared them with Science, which then commissioned independent image analysts and Alzheimer’s researchers to review the same papers.

The reviewers concluded that images in multiple Lesné papers showed signs of manipulation, raising serious questions about the underlying data on Aβ*56. In the months that followed, journals issued expressions of concern, corrections were published, and the 2006 Nature paper was eventually retracted in 2024 after an extended review process by the journal and the authors’ institution. Lesné disputed aspects of the allegations through his university, and the formal investigations into research misconduct moved at the slow pace such inquiries always do.

Here is what the episode did and did not prove, and the distinction matters more than the headlines often suggested. The questioned images concerned a specific amyloid subspecies, Aβ*56, that some researchers had pursued as a potential drug target, and the doubts cast on those particular results undermined that specific line of work. The broader amyloid hypothesis, built on genetic evidence from APP and presenilin mutations and on decades of independent biochemical research, did not rest on Lesné’s images and was not refuted by their problems. Senior Alzheimer’s researchers quoted in the Science investigation made that point repeatedly, even as they acknowledged the damage to public trust.

What the episode did expose was how much weight a single, visually striking finding can carry in a field hungry for a clear culprit, and how long it can take for image problems to surface in a peer-reviewed literature that processes tens of thousands of figures every year. Matthew Schrag became a reluctant public figure in scientific integrity work, and his methods, including careful side-by-side image comparison, were soon being applied to papers in other corners of biomedicine. The Aβ*56 story slid out of the foreground of Alzheimer’s research, and the field’s attention turned back to the broader question of whether any anti-amyloid drug could actually help a living patient.

That question was about to receive its loudest and most contested answer in a generation, inside the conference rooms of the U.S. Food and Drug Administration.

Glen Campbell Stays on Stage

While the FDA was preparing for its first major modern decision on an Alzheimer’s drug, a country music star was already writing the most public diary of the disease that American audiences had ever seen. Glen Campbell, the guitarist and singer behind “Rhinestone Cowboy” and “Wichita Lineman,” was diagnosed with Alzheimer’s disease in 2011 at the age of 75, and his family chose, unusually, to announce it before he stepped onto the road for one last run of shows.

That run became the Goodbye Tour, which ran from 2011 into 2012 and stretched longer than anyone had initially planned because Campbell was still, on most nights, able to play. His children performed alongside him in the touring band, cueing him into songs, covering the moments when the lyrics slipped, and standing close enough on stage to guide him back to the verse if he lost his place. Audiences came knowing what they were watching, and the reviews from that tour describe a strange double experience of seeing a musician disappear and remain in the same evening.

In 2014, the documentary Glen Campbell: I’ll Be Me, directed by James Keach, brought cameras inside the tour and inside the family home. The film showed Campbell forgetting interviews moments after giving them, asking his wife the same questions across a single afternoon, and then walking onto a stage and playing intricate guitar solos that his hands seemed to remember even when his conscious mind did not. Procedural memory, the kind stored in motor circuits built over a lifetime of practice, is often preserved longer in Alzheimer’s than the explicit memory for names and dates, which is why musicians and athletes can sometimes perform skills they can no longer describe.

The film also captured the harder moments away from the stage, including a neurological examination at the Mayo Clinic in which Campbell could not consistently identify the year or the building he was sitting in. His wife Kim and his children appear throughout the documentary as the everyday infrastructure of his continued performing life, managing medications and travel and the dozens of small accommodations that kept him safe on tour. The film closed its theatrical run with a song called “I’m Not Gonna Miss You,” which Campbell recorded after his diagnosis and which his co-writer Julian Raymond has described as his direct response to the disease.

The lyric is unsparing about what was coming and what had already gone, written from the perspective of someone who knows he will eventually lose the person he is singing to. The song was nominated for an Academy Award for Best Original Song in 2015 and won a Grammy that same year for Best Country Song. Campbell continued recording until his voice and stamina would no longer allow it, and he died on August 8, 2017, at the age of 81, after several years out of the public eye in long-term memory care.

Robin Williams and Lewy Body Dementia

A brief note before this next section. We will be discussing the death of the actor Robin Williams in 2014, and we will do so clinically, focused on what his autopsy revealed about a particular form of dementia. If this is difficult to hear, please feel free to skip ahead, and if you are struggling, helplines are available in most countries and are linked in the description below.

Robin Williams was 63 years old when he died on August 11, 2014, at his home in Northern California, and the months leading up to his death had been some of the most medically confusing of his life. In May of that year he had been diagnosed with Parkinson’s disease, and he had spoken privately with friends and family about the tremors, the stiffness, and the rising anxiety that had been disrupting his work and his sleep for many months. The Parkinson’s label gave a name to some of what he was experiencing, but it did not account for the full range of symptoms his family later described in detail.

The autopsy, performed by the Marin County coroner, revealed something his doctors had not been able to see in life. Williams had diffuse Lewy body disease, an aggressive form of the same pathology that drives Lewy body dementia, with widespread deposits of the protein alpha-synuclein throughout his brainstem, his limbic system, and his cortex. Lewy body dementia is the second most common form of progressive dementia after Alzheimer’s disease, and its symptoms include vivid visual hallucinations, dramatic fluctuations in attention and alertness from hour to hour, movement problems similar to Parkinson’s, and a severe sleep disorder in which people act out their dreams physically.

In September 2016, Williams’ widow, Susan Schneider Williams, published a personal essay in the journal Neurology titled “The terrorist inside my husband’s brain.” She wrote about watching her husband move through what she counted as more than forty symptoms in the final year of his life, including paranoia, delusions, insomnia, gastrointestinal distress, and sudden lapses in his ability to remember lines on set. She described doctors searching for explanations one symptom at a time, never assembling them into the single diagnosis that the autopsy would later confirm.

Her essay made several careful points that have shaped how clinicians now talk about the disease publicly. Lewy body dementia is frequently mistaken for Parkinson’s disease, for Alzheimer’s disease, or for primary psychiatric illness, and the wrong diagnosis can lead to the wrong medications, some of which can be dangerous in Lewy body patients because of their severe sensitivity to certain antipsychotic drugs. She also argued that the depression often described as a cause of suffering in such cases can itself be a symptom of the underlying neurological disease, rather than a separate condition layered on top of it.

The Lewy Body Dementia Association reported a sharp rise in family inquiries in the months after Williams’ death and again after his widow’s essay appeared in Neurology. For many caregivers, the public account of a famous patient navigating misdiagnosis put a name to symptoms they had been trying to describe to their own doctors for years without success. The condition remains under-recognized in primary care, and specialist memory clinics continue to see patients who arrive with files full of older, incorrect labels.

One Family’s Day

Step away from the famous names for a moment and into an ordinary home in an ordinary suburb, because this is where most dementia care actually happens. The World Health Organization estimates that informal caregivers, meaning family members and friends who are not paid for the work, provide on average around five hours of care per day to a person living with dementia, and that women provide roughly seventy percent of those caregiving hours worldwide. Those numbers are large and clean on the page, and they flatten an experience that, lived from the inside, is made of thousands of small refusals to walk away.

Consider the medication schedule taped to the refrigerator, the one with the highlighter marks and the times written in capital letters because a missed dose at six in the evening means a worse night at three in the morning. Consider the locks installed on the inside of cabinets that once held only pots and pans, because the person you love has begun mistaking dish soap for something drinkable. Consider the front door that now has a chain higher than eye level, because last winter your father walked out in his pajamas and was found four streets away by a neighbor who recognized him only because they had gone to the same church for thirty years.

Caregivers describe a particular kind of exhaustion that is not exactly physical and not exactly emotional, and that does not lift after a single night of rest because no single night of rest is ever uninterrupted. The same question gets asked at eleven in the evening, then at one in the morning, then again at three, and the patient asking it is genuinely encountering it as new each time. Saying “I already told you” does no good and often makes things worse, so caregivers learn to answer the same question with the same calm voice for the eighth time before sunrise.

The role expands far beyond bedside care into territory most family members never trained for. They become medication managers, safety monitors, insurance negotiators, financial planners, legal proxies, and the emotional shock absorbers for every other relative who calls to ask how things are going without offering to come help. They learn to interpret behaviors that doctors call “neuropsychiatric symptoms” and that the rest of the world might simply call frightening, including agitation, suspicion, and sometimes accusations aimed at the people doing the most to keep them safe.

Researchers and clinicians have a name for the particular grief that runs through this work, and they call it anticipatory grief. It is the experience of mourning someone who is still in the room with you, still drinking coffee at the kitchen table, still recognizable in flashes that arrive without warning and leave the same way. Caregiver depression rates are elevated compared to the general population in studies cited by major dementia organizations, and the risk rises with the duration of caregiving and the severity of the patient’s symptoms.

Speaking of caregivers as heroes, which the press often does, can obscure a more important fact about the work they do. The burden they carry is not the existence of their loved one, who remains a person worthy of care for as long as the disease allows. The burden is the inadequate support around them, the patchwork of services and insurance rules and respite programs that families have to assemble on their own while also keeping someone alive.

The Care Industry’s Promise

For many families, there comes a point when the home arrangement stops being sustainable, and the search begins for somewhere else. In the United States and much of the English-speaking world, that search usually leads to a category of facility known as assisted living, often with a specialized wing or program marketed under the name memory care. These businesses present themselves as a middle ground between independent living and a traditional nursing home, designed for people who need supervision and help with daily activities without requiring hospital-level medical care.

The marketing materials are familiar to anyone who has toured one of these places under pressure. Brochures describe secure units with coded doors that prevent wandering, structured daily routines designed to reduce confusion, staff trained in dementia-specific communication, and activities calibrated to the cognitive abilities of residents. Many facilities are physically attractive, with landscaped courtyards, dining rooms that aim for the feel of a restaurant, and private or semi-private apartments that families can decorate with familiar furniture from home.

The regulatory reality behind those brochures is more complicated than most families realize at the point of move-in. In a 2013 investigation by ProPublica and the PBS series Frontline, reporter A.C. Thompson documented that in many U.S. states, assisted living is regulated more like housing than like healthcare, with rules that vary substantially from one jurisdiction to the next. Minimum staffing ratios are not always set by law, training requirements for direct-care workers are often modest, and oversight inspections can be infrequent compared with the inspections required of skilled nursing facilities.

That structural gap matters more for dementia residents than for almost any other population, because people with moderate to advanced dementia are frequently unable to report neglect or abuse to anyone outside the building. A resident who cannot remember whether they were repositioned in bed cannot tell a family member during a Sunday visit that they were left in the same chair from breakfast to dinner. A resident who cannot reliably describe pain cannot alert staff to a developing infection until it has become a medical emergency.

Families almost always choose facilities under the worst possible conditions for clear thinking. The decision usually arrives after a fall, after a wandering incident, after a hospitalization, or after a caregiver has reached a point of physical collapse, and it has to be made in days or weeks rather than in months of careful comparison. Cost pressures sharpen the urgency further, because in much of the United States assisted living is paid for out of personal savings and home equity rather than through Medicare, and families are watching the meter run from the moment they sign.

It was inside this industry, under these conditions, that a woman named Joan Boice moved into a facility called Emerald Hills in Auburn, California, in September 2008.

Joan Boice and the Verdict

Joan Boice was 81 years old, she had been diagnosed with Alzheimer’s disease, and her family had reached the point at which keeping her safely at home was no longer possible. Emerald Hills was operated at the time by Emeritus Corporation, then one of the largest assisted-living chains in the United States, and the facility offered a dedicated memory care unit that the family understood to be staffed and equipped for residents at Joan’s level of cognitive decline. The Boice family later said in court filings that the admissions process had reassured them their mother would receive the supervision and physical care she could no longer provide for herself.

Joan Boice lived at Emerald Hills for approximately three months, and during that period, according to evidence presented at trial, she developed multiple pressure ulcers, including a severe wound on her lower back that progressed to a stage at which underlying tissue was exposed. Pressure ulcers, sometimes called bedsores, develop when a person is left in the same position for too long without being repositioned, and in immobile or partially mobile residents they are a recognized and largely preventable complication of inadequate nursing care. Joan was hospitalized, transferred out of the facility, and died in early 2009, with the pressure ulcers and resulting complications cited in court as substantial factors in her death.

Her family filed suit against Emeritus Corporation, alleging elder abuse, negligence, and wrongful death, and the case went to trial in Sacramento County Superior Court in 2013. ProPublica and Frontline, working in parallel with the litigation, reported on internal company practices that plaintiffs’ attorneys argued had contributed to the conditions at Emerald Hills, including staffing levels that the family’s lawyers said were inadequate to the acuity of the residents the facility had accepted. Emeritus disputed the characterization of its operations and defended the care provided at the facility throughout the proceedings.

In May 2013, the jury returned a verdict in favor of the Boice family, finding Emeritus liable for elder abuse, negligence, and wrongful death, and awarding compensatory and punitive damages that initially totaled hundreds of millions of dollars. The trial judge later reduced the award substantially, and in June 2013 the court upheld a final judgment of roughly 23 million US dollars, as reported by KCRA and the Associated Press. The judge’s ruling included pointed language about the company’s conduct, and the verdict became one of the most prominent assisted-living elder-abuse judgments in recent American legal history.

A note on the corporate timeline matters here for accuracy. In 2014, after the Boice verdict, Emeritus Corporation was acquired by Brookdale Senior Living, which became the largest senior-living operator in the United States through that merger. The findings of fact in the Boice case belong to Emeritus, the company that operated Emerald Hills at the time Joan lived there, and reporting on the case attributes the conduct accordingly rather than extending it to the acquiring company that took on the operations afterward.

The harder question raised by the verdict is the one regulators and families have wrestled with in the decade since. How does an industry built around the promise of safety for cognitively vulnerable residents produce cases like Joan Boice’s at all, and what specific regulatory changes have followed in the states where such cases have been documented? Reform proposals after the ProPublica and Frontline reporting included stricter staffing rules, mandatory dementia training, and clearer admissions criteria for memory care units, but uptake has varied widely by state, and federal oversight of assisted living remains far thinner than the oversight of skilled nursing facilities funded by Medicare and Medicaid.

When Wandering Becomes Law

So, return for a moment to that morning in Aichi, and to the man whose family had sewn identification into the lining of his clothes. By the time his case reached the Supreme Court of Japan in 2016, lower courts had already ruled twice that his relatives owed JR Central money for the disruption his death had caused on the rail line. The Nagoya District Court in 2013 ordered the family to pay the full 7.2 million yen, and the Nagoya High Court in 2014 reduced the figure to around 3.6 million yen while keeping the wife on the hook for her husband’s actions.

The widow at the center of the case was 85 years old at the time of the incident, and she had her own care needs that limited how closely she could shadow her husband through the house. Their eldest son, who shared legal responsibility under the high court’s reasoning, lived hundreds of kilometers away in Yokohama and had not been physically present that day. The lower courts had nonetheless held that a spouse with a statutory duty of supervision could be liable when a person judged incapable of responsibility caused damage to a third party.

On March 1, 2016, the Supreme Court reversed those decisions and ruled that the family was not automatically liable for the railway’s losses. The judgment, as reported by the Asahi Shimbun and J-Cast News, did not say that families with a relative living with dementia could never bear responsibility for harm caused by that relative. It said that liability had to be assessed case by case, looking at the actual living arrangement, the physical capacity of the caregiver, and the practical possibility of supervision under real conditions.

For the widow in Aichi, the court found, those conditions made automatic liability unreasonable. She was elderly, she was frail, and the idea that she could have prevented her 91-year-old husband from leaving the house during a brief lapse stretched the legal duty of supervision past the point where it matched daily life. The son in Yokohama, the court reasoned, could not be treated as a constant supervisor of a father he did not live with.

Here’s the thing — the ruling landed in a country where the scale of dementia-related wandering had already moved far beyond the courtroom. The National Police Agency of Japan reported that more than 10,000 people with dementia were recorded as missing in 2015, and that figure has risen in subsequent annual reports as the population has aged further. Municipalities from Fukuoka to Sendai have built volunteer search networks, drills with local schools, and registries where families can submit photographs and physical descriptions in advance.

Some towns have experimented with QR-coded stickers placed on fingernails or clothing, which a stranger can scan to contact a registered caregiver, and others have funded GPS-enabled shoes through local welfare budgets. Dementia advocates in Japan welcomed the 2016 ruling as a recognition that the duty of care could not rest entirely on exhausted spouses and distant children. Legal scholars, writing in Japanese law journals after the decision, noted that the court had left open the question of who, if not the family, should bear the residual cost of incidents like the one at Kyowa Station.

JR Central walked away from the case without compensation, and the railway has not, in public statements, pursued similar claims against caregivers in subsequent wandering deaths along its lines. The widow died a few years after the ruling, out of the public eye, and her name was kept out of most reporting at the family’s request. The legal precedent her case set continues to be cited in Japanese tort textbooks under the heading of supervisory liability for persons lacking capacity.

Designing Around the Disease

So, if families cannot do it alone, and courts cannot fix it after the fact, what does a society actually build for people living with dementia? Two answers have taken shape over the last two decades, one behind a wall and one without one.

The wall belongs to De Hogeweyk, a residential complex in the town of Weesp in the Netherlands, which opened in December 2009 on the site of a former traditional nursing home. The facility was designed by the nonprofit Vivium Zorggroep for residents with severe dementia, and it houses roughly 150 to 170 people across a cluster of small group homes built around streets, a square, a supermarket, a café, and a theater. Staff work in ordinary clothes rather than uniforms, residents shop for groceries with assistance, and the perimeter is secured so that residents can move freely inside the village without being able to wander into traffic outside.

The model does not claim to cure dementia or to slow its biology, and the leadership at Hogeweyk has been careful in interviews to push back against journalists who describe it as a miracle. What it changes is the environment around the disease, so that a resident who wants to walk meets a familiar street rather than a locked corridor. Larissa MacFarquhar, writing in The New Yorker in October 2018, called the approach a system of “comforting fictions,” and her piece explored the ethical question of whether arranging a simulated normal life for people who can no longer follow the real one is a form of kindness or a form of deception.

That question does not have a settled answer, and Hogeweyk-inspired projects have since opened in countries from Denmark to Canada with varying degrees of fidelity to the original design. Critics point out that the per-resident cost is substantial, and that Dutch long-term care funding makes the model possible in ways that do not transfer easily to countries with thinner public insurance.

Outside the wall, a different strategy has spread more widely under the banner of dementia-friendly communities. Japan launched the Ninchisho Supporter Caravan in 2005, a national program that trains ordinary citizens in basic dementia awareness through short courses run by local governments and community groups. The Japanese Ministry of Health, Labour and Welfare has reported that more than 14 million people had completed the training by the early 2020s, including bank tellers, bus drivers, schoolchildren, and convenience-store staff.

The United Kingdom built a parallel program called Dementia Friends, launched by the Alzheimer’s Society in 2013, which by its own published figures has trained several million people in England, Wales, and Northern Ireland. France has piloted a “village landais” project in the town of Dax in the southwest, which opened in 2020 with a layout influenced by Hogeweyk but funded through a mix of public and departmental support. Each program rests on the same underlying bet, which is that a shopkeeper who recognizes confusion can guide a customer home rather than calling the police on someone who has forgotten where they parked.

The ethical tensions inside these programs are real and unresolved. GPS trackers and QR identification tags raise privacy questions for people who can no longer consent to being monitored, and the line between protection and surveillance grows thinner as the technology improves. Advocates argue that the alternative, which is the death at Kyowa Station and the lawsuit that followed it, sets a clear floor under what civic infrastructure for dementia has to look like.

The Ethics of a Future Self

In April 2016, in a nursing home in the Netherlands, a 74-year-old woman with severe Alzheimer’s disease was given a lethal dose of medication by her physician, in accordance with the Dutch euthanasia law and with an advance directive she had written years earlier while still legally competent. The case became the first prosecution of a doctor under the Netherlands’ Termination of Life on Request and Assisted Suicide Act since the law took effect in 2002. The patient and the doctor were not named in public records, and reporting in the Washington Post and Dutch outlets has referred to them only by role.

The woman had been diagnosed with Alzheimer’s several years earlier, and she had drafted a written directive requesting euthanasia when her suffering became unbearable and when she could no longer recognize her family. The directive was reviewed by her general practitioner and updated as her condition changed, and by 2016 she had been moved into residential care because her husband could no longer manage her at home. By the time the procedure was carried out, she was no longer able to consistently affirm or refuse the request she had written years earlier.

Dutch prosecutors charged the physician, a geriatrician who had taken over her care at the nursing home, with failing to verify the patient’s current wishes adequately before proceeding. The case proceeded through the Hague District Court in 2019, and on September 11 of that year the court acquitted the doctor of all charges. The judges ruled that the physician had acted with due care under the law, that the advance directive was valid, and that requiring renewed consent from a patient already in advanced dementia would have rendered the directive meaningless.

In April 2020, the Dutch Supreme Court upheld the acquittal and clarified that doctors carrying out euthanasia under a written advance directive in advanced dementia would not face criminal liability where statutory due-care criteria were met. The Royal Dutch Medical Association subsequently updated its professional guidance on advance directives in dementia, setting out how physicians should document conversations and assess suffering when the patient can no longer speak for themselves.

The legal question was resolved within the Dutch system, and the philosophical question was not, because no court ruling can settle it. The case sits on a fault line that runs through modern medical ethics, and it has been argued on both sides by people acting in good faith. On one side is the principle of prior autonomy, which holds that a person of sound mind has the right to bind their future self to decisions about a life they can foresee but not yet inhabit. The directive is, on this view, the only voice the earlier self will ever have once the disease has progressed, and ignoring it is a different kind of abandonment.

On the other side is the principle of present vulnerability, which holds that the person in the bed is the person who matters now, and that someone who can no longer affirm a past decision cannot meaningfully be said to be exercising it. Disability advocates and some palliative-care physicians have argued that advance directives in dementia risk treating cognitive change itself as a fate worse than death, and that the framework can pressure patients toward early decisions they might not make if better care were available.

The Netherlands permits this procedure only under strict statutory conditions, and most countries do not permit it at all in cases of advanced dementia, including most jurisdictions in North America and most of the European Union. The Le Monde comparison published in April 2024 set out how France, Belgium, Spain, and other neighbors draw the line in different places along this spectrum. The Dutch case did not resolve the underlying ethical question for any of them, and it remains one of the sharpest unresolved questions in the medicine of cognitive decline.

The Dementia Bill Comes Due

The arithmetic of dementia stopped being a clinical question a long time ago, and it has become a planning question for finance ministries. The World Health Organization put the global cost of dementia at roughly 1.3 trillion US dollars in 2019, with about half of that figure representing the unpaid labor of family members rather than billed medical care. Projections cited in the same WHO materials suggest that the annual total will continue to climb as the global caseload moves toward 152.8 million people by 2050.

Governments have been writing plans against those numbers for more than a decade now, with varying degrees of follow-through. In the United States, President Barack Obama signed the National Alzheimer’s Project Act into law on January 4, 2011, creating a federal coordinating structure and committing the country to a national plan with the stated goal of preventing or effectively treating Alzheimer’s disease by 2025. The act required annual updates and a standing advisory council, and federal Alzheimer’s research funding through the National Institutes of Health rose substantially in the years that followed, though the 2025 treatment goal arrived without being met.

Japan moved on a parallel track with the Orange Plan, launched by the Ministry of Health, Labour and Welfare in 2012, and updated as the New Orange Plan in January 2015. The plans set numerical targets for early diagnosis, for the expansion of community support centers, and for the training of citizens through the Ninchisho Supporter Caravan we mentioned earlier. The United Kingdom announced the Prime Minister’s Challenge on Dementia under David Cameron in March 2012, with a refreshed version, Challenge on Dementia 2020, published three years later.

At the international level, the World Health Assembly adopted the Global Action Plan on the Public Health Response to Dementia 2017 to 2025 in May 2017, asking member states to coordinate work across awareness, risk reduction, diagnosis, and caregiver support. The G8 Dementia Summit hosted by the UK in December 2013 had set the political tone for that decade by committing participating governments to accelerate research, with reporting in the BMJ describing an ambition framed around finding a disease-modifying treatment by 2025.

Behind all of these documents sits a workforce problem that no plan has yet solved. There are not enough trained dementia caregivers for the 57 million people already living with the disease, let alone for the 152.8 million projected by mid-century, and care-worker turnover in the United States and the United Kingdom routinely runs above 30 percent annually in published industry surveys. Wages in direct-care work remain low across most high-income countries, immigration restrictions have tightened the supply of foreign-born caregivers in several economies, and lower-income countries face the steepest projected increases in cases with the thinnest existing infrastructure.

What We Still Don’t Know

The honest list of open questions in dementia science is longer than the list of settled facts, and the field has grown more candid about that in recent years. One of the most stubborn puzzles concerns the relationship between brain pathology and lived symptoms, because autopsy studies have repeatedly identified people who died with extensive amyloid plaques and tau tangles while remaining cognitively intact into their final months. Other patients decline rapidly with relatively modest pathology, and no current biomarker reliably predicts which path a given individual will follow.

The amyloid hypothesis itself has taken hits even from drugs that did exactly what the theory predicted. Solanezumab, an antibody developed by Eli Lilly that targets soluble amyloid, failed to show meaningful clinical benefit across the EXPEDITION trials and was reported in 2023 to have missed its endpoints in the A4 prevention study in people with early amyloid accumulation. The failures did not refute the broader hypothesis, but they complicated the simplest version of it, and they pushed researchers to look at tau, inflammation, and vascular contributions with renewed attention.

A newer line of inquiry concerns the GLP-1 receptor agonists, the class of drugs that includes semaglutide and that has reshaped the treatment of diabetes and obesity over the past decade. Novo Nordisk has been running phase three trials called EVOKE and EVOKE Plus testing oral semaglutide in early Alzheimer’s disease, with results expected to read out in the coming years. Whether a drug developed for blood sugar will turn out to influence the trajectory of dementia is genuinely unknown at the time of this recording.

Biomarker testing has created its own ethical territory that medicine has not yet mapped completely. Blood tests for amyloid and tau are moving rapidly into wider clinical use, and they make it possible to tell a healthy 55-year-old that they are very likely to develop Alzheimer’s disease in the decades ahead, at a moment when no treatment can reliably change that outcome. Specialists in memory clinics report that some patients want that information and others firmly do not, and the field is still working out how to offer testing responsibly under those conditions.

Incidence data add one more layer of uncertainty to the picture. Several large studies in high-income countries, including the Framingham Heart Study cohort and analyses from the United Kingdom, have suggested that age-specific dementia incidence has been declining in recent decades, possibly because of better cardiovascular care and rising education levels. Other regions, particularly parts of Asia and sub-Saharan Africa, are seeing rising age-specific rates alongside the demographic surge, and the global total continues to climb even where individual risk at a given age may be falling.

”I Have Lost Myself”

Return one last time to Frankfurt, in November 1901, and to the consulting room where Alois Alzheimer sat across from his 51-year-old patient with a notebook open on the table between them. He had asked her to write her own name, and after several attempts that did not resolve into letters, Auguste Deter said, in German, “Ich habe mich verloren.” The phrase translates as “I have lost myself,” and it appears in the case notes that historians of medicine recovered from the Frankfurt archive in the 1990s.

She said it more than a hundred years ago, before the disease that would eventually carry her doctor’s name had been described in any textbook. She said it before Emil Kraepelin would borrow that name in 1910, before George Glenner and Caine Wong would isolate beta-amyloid in 1984, before the Colombian families in Antioquia would be enrolled in prevention trials, and before any of the drugs, lawsuits, national plans, or ethics cases in this episode existed.

There are about 57 million people living with dementia in the world today, according to the World Health Organization. The projection from the Institute for Health Metrics and Evaluation puts the figure at 152.8 million by 2050. Each of those numbers contains a sentence very much like the one Auguste wrote down for her doctor in Frankfurt, in a language her doctor understood, on a day she could no longer write her own name.

The Supreme Court of Japan, ruling in March 2016, did not answer the question that this episode opened with at Kyowa Station. It said only that the answer cannot be a single exhausted spouse, alone in a house, holding the door.

Key Takeaways

• Dementia is a syndrome caused by various diseases that damage the brain, leading to progressive problems with memory, thinking, and daily tasks.
• Alzheimer’s disease is the most common cause of dementia, accounting for 60-70% of cases, with other types including vascular, Lewy body, and frontotemporal dementia.
• The global cost of dementia is staggering, with informal caregivers providing significant unpaid labor, and women bearing a disproportionate burden.
• Early diagnosis and supportive care are crucial, as current medications only temporarily alleviate symptoms without stopping the disease’s progression.
• Legal and ethical questions surrounding dementia care are complex, including issues of liability, assisted living regulations, and end-of-life decisions.

Frequently Asked Questions

What is dementia?

Dementia is a syndrome, which means a recognizable pattern of symptoms produced by a range of underlying diseases and injuries that damage the brain over time. Those symptoms typically include progressive problems with memory, thinking, language, judgment, behavior, and the ordinary tasks of daily life like dressing, cooking, or handling money.

What is the most common cause of dementia?

Alzheimer’s disease is the most common cause, accounting for somewhere between 60 and 70 percent of cases worldwide.

Is dementia a normal part of aging?

No, dementia is not a normal part of getting older, even though its risk does rise sharply with age.

What are the early signs of dementia?

Early signs of dementia include repeating the same questions in a single conversation, losing track of what day or season it is, struggling to find ordinary words, and mishandling familiar tasks such as paying a recurring bill or following a recipe.

What is the global cost of dementia?

The global cost of dementia was around 1.3 trillion US dollars as of 2019, with about half of that figure representing the unpaid labor of family members.

What is the projected number of people living with dementia by 2050?

The global figure could reach roughly 152.8 million people by the year 2050.

What is the amyloid cascade hypothesis?

The amyloid cascade hypothesis suggests that the abnormal buildup of beta-amyloid is the initiating event in Alzheimer’s disease, and that everything else, including the tau tangles, the inflammation, and the eventual death of neurons, flows downstream from that first protein going wrong.

What is the significance of the Paisa mutation in Alzheimer’s research?

The Paisa mutation is a specific presenilin-1 mutation found in an extended family in Colombia. Carriers reliably develop mild cognitive impairment in their mid-forties and full dementia by their early fifties, making them a crucial population in global Alzheimer’s research.

What is the role of informal caregivers in dementia care?

Informal caregivers, typically family members and friends, provide on average around five hours of care per day to a person living with dementia. Women provide roughly seventy percent of those caregiving hours worldwide.

What is the ethical debate surrounding advance directives in dementia?

The ethical debate involves the principle of prior autonomy, which holds that a person of sound mind has the right to bind their future self to decisions about a life they can foresee but not yet inhabit, versus the principle of present vulnerability, which holds that the person in the bed is the person who matters now.

Sources

• Original Into the Shadows video: Alzheimer’s: The Disease That Steals Your Mind
• Hero image source by Suikotei / openverse, by.

Related Coverage